Cargando…

Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study

BACKGROUND: Currently, it is well recognized that response to neoadjuvant chemotherapy is an important predictive factor for survival in breast cancer patients. However, it is still an area of research about which patient would respond to the neoadjuvant chemotherapy. METHODS: Serum CK18 levels were...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendawy, Shimaa R, Mansour, Mostafa, Hamed, Manar, Hossam, Amr, Ramez, Ahmed M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334074/
https://www.ncbi.nlm.nih.gov/pubmed/36974552
http://dx.doi.org/10.31557/APJCP.2023.24.3.969
_version_ 1785070789091917824
author Hendawy, Shimaa R
Mansour, Mostafa
Hamed, Manar
Hossam, Amr
Ramez, Ahmed M
author_facet Hendawy, Shimaa R
Mansour, Mostafa
Hamed, Manar
Hossam, Amr
Ramez, Ahmed M
author_sort Hendawy, Shimaa R
collection PubMed
description BACKGROUND: Currently, it is well recognized that response to neoadjuvant chemotherapy is an important predictive factor for survival in breast cancer patients. However, it is still an area of research about which patient would respond to the neoadjuvant chemotherapy. METHODS: Serum CK18 levels were measured using ELISA from 52 newly diagnosed breast cancer patients, at presentation and after first cycle of neo-adjuvant chemotherapy. Pre- and post-treatment CK-18 levels were correlated with several clinical and pathological parameters. At the end of neoadjuvant treatment, changes in serum CK18 levels were correlated with tumors’ response to therapy. RESULTS: Significant elevation of pre-chemotherapy CK18 level was observed in patients who had progressive disease compared to those who had complete or partial response to therapy (P=0.006 and P<0.001, respectively). Significantly higher CK18 levels were observed post-chemotherapy in complete and partial responders, in contrast to patients with stable or progressive disease (P=0.012% and P=0.001%, respectively). The percent of change was significantly higher in complete responders compared to patients who had stable or progressive disease (P=0.043% and P=0.045%, respectively). CONCLUSION: Our results suggest that patients with increasing CK18 level following chemotherapy are potential responders to their neoadjuvant protocol. Thus, the measurement of serum CK18 early in the treatment course could be a simple, noninvasive way to predict tumor response to neoadjuvant chemotherapy.
format Online
Article
Text
id pubmed-10334074
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-103340742023-07-12 Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study Hendawy, Shimaa R Mansour, Mostafa Hamed, Manar Hossam, Amr Ramez, Ahmed M Asian Pac J Cancer Prev Research Article BACKGROUND: Currently, it is well recognized that response to neoadjuvant chemotherapy is an important predictive factor for survival in breast cancer patients. However, it is still an area of research about which patient would respond to the neoadjuvant chemotherapy. METHODS: Serum CK18 levels were measured using ELISA from 52 newly diagnosed breast cancer patients, at presentation and after first cycle of neo-adjuvant chemotherapy. Pre- and post-treatment CK-18 levels were correlated with several clinical and pathological parameters. At the end of neoadjuvant treatment, changes in serum CK18 levels were correlated with tumors’ response to therapy. RESULTS: Significant elevation of pre-chemotherapy CK18 level was observed in patients who had progressive disease compared to those who had complete or partial response to therapy (P=0.006 and P<0.001, respectively). Significantly higher CK18 levels were observed post-chemotherapy in complete and partial responders, in contrast to patients with stable or progressive disease (P=0.012% and P=0.001%, respectively). The percent of change was significantly higher in complete responders compared to patients who had stable or progressive disease (P=0.043% and P=0.045%, respectively). CONCLUSION: Our results suggest that patients with increasing CK18 level following chemotherapy are potential responders to their neoadjuvant protocol. Thus, the measurement of serum CK18 early in the treatment course could be a simple, noninvasive way to predict tumor response to neoadjuvant chemotherapy. West Asia Organization for Cancer Prevention 2023 /pmc/articles/PMC10334074/ /pubmed/36974552 http://dx.doi.org/10.31557/APJCP.2023.24.3.969 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Research Article
Hendawy, Shimaa R
Mansour, Mostafa
Hamed, Manar
Hossam, Amr
Ramez, Ahmed M
Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study
title Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study
title_full Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study
title_fullStr Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study
title_full_unstemmed Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study
title_short Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study
title_sort serum cytokeratin 18 as a potential early marker for chemotherapy response in breast cancer patients: a prospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334074/
https://www.ncbi.nlm.nih.gov/pubmed/36974552
http://dx.doi.org/10.31557/APJCP.2023.24.3.969
work_keys_str_mv AT hendawyshimaar serumcytokeratin18asapotentialearlymarkerforchemotherapyresponseinbreastcancerpatientsaprospectivestudy
AT mansourmostafa serumcytokeratin18asapotentialearlymarkerforchemotherapyresponseinbreastcancerpatientsaprospectivestudy
AT hamedmanar serumcytokeratin18asapotentialearlymarkerforchemotherapyresponseinbreastcancerpatientsaprospectivestudy
AT hossamamr serumcytokeratin18asapotentialearlymarkerforchemotherapyresponseinbreastcancerpatientsaprospectivestudy
AT ramezahmedm serumcytokeratin18asapotentialearlymarkerforchemotherapyresponseinbreastcancerpatientsaprospectivestudy